Jobs
-
Full abstracts for posters and for podium presentations should be submitted by July 27, 2011. Beginning May 1, abstracts can be submitted on-line at www.ddl-conference.org.uk. Researchers studying for a degree or up to three years… Read more . . .
-
Kohlberg Kravis Roberts & Co (KKR) will buy Pfizer’s Capsugel business for just under $2.4 billion. In addition to its Vcaps hydroxypropyl methyl cellulose (HPMC) capsules for dry powder inhalation products, Capsugel also manufactures the… Read more . . .
-
Soon after announcing positive Phase 3 results for Dymista and saying that it would file an NDA for the product by mid-2011, Meda announced that it has gone ahead with the filing. Dymista is a… Read more . . .
-
The Office of Biomedical Advanced Research and Development Authority (BARDA), an agency within the US Department of Health and Human Services under the Office of the Assistant Secretary for Preparedness and Response, has awarded a… Read more . . .
-
Speakers representing the FDA and several IPAC-RS working groups dominated day 2 of the 2011 IPAC-RS conference, with presentations and panel discussions on the day’s main topic, “Product Quality.” The day began with the keynote… Read more . . .
-
Day 1 of the 2011 IPAC-RS conference featured 13 talks and a panel discussion, covering two topics aligned with the conference theme of “Bring Value to the Patient in a Changing World.” The morning focus,… Read more . . .
-
According to Meda Pharmaceuticals, a Phase 3 trial has shown that its Dymista nasal spray, a combination formulation of azelastine hydrochloride and fluticasone propionate, produced a 40% greater improvement in nasal symptoms than fluticasone alone.… Read more . . .
-
Vectura’s VR496, an inhaled dry powder formulation of heparin sodium, has produced positive results in a Phase 2 study in cystic fibrosis patients, says the company. The product has received orphan drug status from both… Read more . . .
-
Results from the Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD) study published in the New England Journal of Medicine show a significant reduction in exacerbations for COPD patients treated with tiotropium compared to those… Read more . . .
-
The FDA has informed Novartis that it needs a three-month extension for its review of data supporting the company’s NDA for QAB149 (indacaterol). The new completion date for the review would be July 2011. The… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.